R&D channel feed

Iver­ic, Astel­las eye US la­bel ex­pan­sion for ge­o­graph­ic at­ro­phy drug af­ter pos­i­tive two-year da­ta

Last year
Pharma

Ex­clu­sive: GSK re­vamps its re­search strat­e­gy, build­ing three teams to tar­get spe­cif­ic dis­ease spaces

Last year
People
Pharma

In the Lab: Re­gen­eron brings its an­ti­body chops to gene edit­ing's biggest prob­lem, aim­ing to 'change the field'

Last year
In Focus

BioN­Tech nabs up to $90M for mpox vac­cine as it be­gins PhI/II tri­al be­hind Mod­er­na's lead

Last year
Financing
Pharma

An­thos to stop fac­tor XI tri­al in atri­al fib­ril­la­tion ear­ly af­ter 'over­whelm­ing ben­e­fit'

Last year

FDA ap­proves GSK's JAK in­hibitor for rare blood can­cer af­ter three-month de­lay

Last year

Late­com­er Am­gen takes 'plat­form ap­proach' in obe­si­ty as PhII da­ta loom

Last year
Pharma

MAPS plans to seek ap­proval of MD­MA-as­sist­ed ther­a­py this year af­ter sec­ond pos­i­tive PhI­II tri­al

Last year

Bris­tol My­ers cuts mid-stage NASH, an­ti-TIG­IT pro­grams

Last year

Ab­b­Vie turns its back on Har­poon’s BC­MA-tar­get­ing mul­ti­ple myelo­ma drug

Last year
Deals

Mod­er­na cuts four pro­grams in vac­cines, sol­id tu­mors and heart fail­ure as it in­creas­es, pri­or­i­tizes pipeline

Last year

Gene ther­a­py biotech Alveo­Gene launch­es with lentivi­ral plat­form for res­pi­ra­to­ry dis­eases

Last year
Startups
Cell/Gene Tx

FDA sets spring de­ci­sion date for Madri­gal’s NASH treat­ment, days af­ter com­pa­ny an­nounced new CEO

Last year
FDA+

Af­ter an $80M Se­ries D raise, Dal­Cor takes an­oth­er shot at a PhI­II my­ocar­dial in­farc­tion tri­al

Last year
Financing

MaaT Phar­ma and CD­MO Skyephar­ma un­veil be­spoke, and po­ten­tial­ly largest, mi­cro­bio­me fa­cil­i­ty in Eu­rope

Last year
Manufacturing

Neu­ro­crine plots 2024 fil­ing for rare dis­ease drug af­ter 'solid' PhI­II win

Last year

Eiger ends PhI­II he­pati­tis delta tri­al over safe­ty con­cerns — and the search for treat­ment part­ner

Last year

Mod­er­na CEO shares bold new vi­sion: 15 new prod­ucts and 50 new clin­i­cal can­di­dates in five years

Last year

Mironid reach­es $43.7M to date in Se­ries A ex­ten­sion to fund kid­ney dis­ease treat­ment stud­ies

Last year
Financing

WCLC roundup: As­traZeneca, Am­gen, J&J and Hutchmed tout new com­bi­na­tion or con­fir­ma­to­ry da­ta

Last year
Pharma

Ahead of ad­comm, FDA ques­tions ef­fi­ca­cy of Al­ny­lam's patisir­an in dis­abling rare con­di­tion AT­TR-CM

Last year

San Diego biotech starts clin­i­cal study of self-repli­cat­ing RNA vac­cine for ra­bies

Last year

Lyra touts pos­i­tive topline PhII da­ta for chron­ic rhi­nos­i­nusi­tis drug

Last year

Rome Ther­a­peu­tics ad­vances dark genome drug af­ter com­plet­ing $72M Se­ries B ex­ten­sion backed by Big Phar­ma

Last year
Financing
First page Previous page 71727374757677 Next page Last page
A service from the Financial Times